Altis Labs raises $25 million Series A for AI model that predicts patient survival from CT scans
| Source: Techmeme | Original article
Altis Labs, an AI firm that predicts patient survival from CT scans in oncology trials, secured a $25 million Series A funding round.
Altis Labs, a Copenhagen‑based AI software firm that builds models for drug development, announced a $25 million Series A financing round. The capital, raised from a group of undisclosed investors, will be used to expand the company’s platform that interprets computed‑tomography (CT) scans collected during oncology clinical trials and generates survival‑related predictions for patients.
The company’s core technology applies deep‑learning techniques to imaging data, extracting patterns that correlate with treatment outcomes. By linking scan features directly to survival metrics, the model promises to give researchers an early, quantitative read‑out of a drug’s efficacy, potentially shortening trial timelines and reducing costs. In a field where biomarker discovery often relies on invasive biopsies or lengthy follow‑up, a non‑invasive imaging predictor could shift how early‑phase oncology studies are designed and evaluated.
The financing underscores growing investor confidence in AI‑driven drug discovery tools, especially those that bridge the gap between raw clinical data and actionable insights. It also places Altis Labs among a handful of European startups seeking to commercialise medical‑imaging AI beyond radiology diagnostics, targeting the pharmaceutical pipeline instead.
Going forward, the company’s next milestones will likely involve clinical validation of its model across multiple trial cohorts and regulatory engagement to define its role in trial endpoints. Observers will watch for partnerships with major pharma sponsors and any data releases that demonstrate predictive accuracy in real‑world trial settings. Success could accelerate the adoption of AI‑based imaging biomarkers across the drug development ecosystem.
Sources
Back to AIPULSEN